The BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics
Details
Publication Year 2010-08-15,Volume 185,Issue #4,Page 2555-2562
Journal Title
JOURNAL OF IMMUNOLOGY
Publication Type
Journal Article
Abstract
Mast cells and their mediators are implicated in the pathogenesis of many different diseases. One possible therapeutic intervention in mast cell-associated diseases can be to reduce the number of tissue mast cells by inducing mast cell apoptosis. In this study, we demonstrate that mast cells exhibit a high sensitivity to ABT-737, a BH3-only mimetic molecule that induces apoptosis through high-affinity binding to the prosurvival proteins, Bcl-2, Bcl-XL, and Bcl-w. Primary mast cells as well as mast cell lines tested succumbed to apoptosis in response to the inhibitor at varying but seemingly low concentrations compared with other leukocytes investigated. I. p. injections of ABT-737 in mice resulted in a total abolishment of mast cells in the peritoneum. Confocal microscopy analysis of peritoneal cells revealed apoptotic bodies of mast cells being phagocytosed by macrophages. In addition, ex vivo treatment of human skin biopsies with ABT-737 demonstrated increased mast cell apoptosis. The data we present in this article show exceptional mast cell sensitivity to ABT-737, a selective inhibitor of antiapoptotic proteins, rendering a possible application for BH3-only mimetic compounds like ABT-737 in mast cell-associated diseases, such as mastocytosis, allergy, asthma, and other chronic inflammations. The Journal of Immunology, 2010, 185: 2555-2562.
Publisher
AMER ASSOC IMMUNOLOGISTS
Keywords
BCL-2 FAMILY-MEMBERS; SMALL-MOLECULE INHIBITOR; IGE-RECEPTOR ACTIVATION; BH3 MIMETIC ABT-737; FC-EPSILON-RI; TRANSCRIPTIONAL INDUCTION; ANTAGONIST ABT-737; X-L; SURVIVAL; DEATH
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2010-08-15 12:00:00
An error has occurred. This application may no longer respond until reloaded. Reload 🗙